Telehealth After the Pandemic: Evidence on Effectiveness and Access

The COVID-19 pandemic forced a rapid and large-scale expansion of telehealth services, driven by the combination of in-person care restrictions and emergency regulatory changes that enabled remote delivery of care across state lines, expanded covered services, and allowed audio-only visits. Between 2019 and 2020, telehealth visits increased by more than 4,000 percent in some healthcare systems. This rapid scaling created the largest real-world experiment in telehealth delivery ever conducted, and researchers have been analyzing the results since. The evidence on telehealth effectiveness for specific conditions has grown substantially during and after the pandemic. For mental health conditions, particularly depression and anxiety, telehealth consistently shows outcomes comparable to in-person care in well-designed studies. The accessibility advantages of telehealth for mental health, including reduced travel burden, elimination of commute, and reduced stigma in some populations, have led to increased utilization and in some studies to reduced dropout from treatment. The evidence for telehealth in behavioral health is among the strongest across all service types. For primary care, telehealth has shown effectiveness for management of chronic conditions including hypertension, diabetes, and certain respiratory conditions. Video visits allow clinicians to observe patients, discuss symptoms, and adjust medications, although they cannot replicate physical examination. Studies of chronic disease management through telehealth generally find comparable outcomes to in-person visits for conditions not requiring physical examination, with advantages in patient convenience and medication adherence in some populations. Dermatology and certain specialty consultations, including neurology for some conditions, have adapted well to telehealth models. Dermatology, which relies heavily on visual assessment, was an early adopter of asynchronous store-and-forward telehealth, in which images are sent to dermatologists for assessment without real-time interaction. Research on teledermatology shows diagnostic accuracy comparable to in-person evaluation for many conditions. The populations that have benefited most from telehealth expansion are those for whom access barriers were most significant before the pandemic. Rural patients, who previously faced long travel distances to specialist care, have accessed specialty services through telehealth that were previously unavailable or rarely used. Patients with disabilities or mobility limitations have accessed care more easily. Working parents have accessed appointments without taking full days off work. These access benefits are real and documented. The populations for whom telehealth has been less accessible include those without reliable broadband internet, those who lack smartphones or computers, those who are not comfortable with technology, and those who have communication needs not well-served by video interaction. Research on the digital divide in telehealth access documents that older adults, low-income individuals, and people of color are less likely to have completed telehealth visits, potentially widening access disparities even as overall utilization has increased. Audio-only visits, which were authorized during the pandemic for situations where video was not available, served as an important access bridge for patients unable to use video. Research on audio-only visits finds them effective for certain types of counseling and care management, though less so than video for conditions where visual assessment adds value. The continuation of audio-only coverage has been debated, with patient advocates arguing that audio-only access is essential for populations that cannot use video. Regulatory questions about telehealth's post-pandemic future have been significant. The emergency regulatory flexibilities that enabled the pandemic-era expansion were temporary, tied to the public health emergency declaration. Congress and the Centers for Medicare and Medicaid Services have extended many of these flexibilities through several rounds of legislation and rulemaking, but the long-term regulatory framework remains unsettled. Issues include interstate licensure, in-person visit requirements for prescribing certain medications, parity of coverage and reimbursement for telehealth versus in-person visits, and facility fee requirements. The evidence base for telehealth continues to develop, and the field has moved from feasibility questions toward more sophisticated comparative effectiveness research. The overall picture is that telehealth is an effective complement to in-person care for a significant range of conditions and populations, that access benefits are real, and that ongoing attention to digital equity is necessary to ensure that telehealth expansion does not create new access disparities alongside the improvements it provides.